NASDAQ:CYTR - CytRx Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.29 -0.03 (-2.27 %)
(As of 05/25/2018 12:31 PM ET)
Previous Close$1.32
Today's Range$1.26 - $1.32
52-Week Range$1.24 - $6.00
Volume9,000 shs
Average Volume448,275 shs
Market Capitalization$44.40 million
P/E Ratio-0.86
Dividend YieldN/A
Beta2.04

About CytRx (NASDAQ:CYTR)

CytRx logoCytRx Corporation, a biopharmaceutical company, engages in the research and clinical development of novel anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of drug at the tumor. The company is developing its pipeline of oncology candidates at its laboratory facilities in Freiburg, Germany, through its LADR (linker activated drug release) technology platform, a discovery engine designed to leverage its expertise in albumin biology and linker technology for the development of anti-cancer therapies. Its lead drug candidate is Aldoxorubicin, an improved version of anti-cancer drug doxorubicin out-licensed to NantCell, Inc. Aldoxorubicin is in late-stage clinical development for the treatment of relapsed soft tissue sarcoma, as well as evaluating in various other cancer indications with unmet clinical need, including small-cell lung cancer. CytRx Corporation was founded in 1985 and is headquartered in Los Angeles, California.

Receive CYTR News and Ratings via Email

Sign-up to receive the latest news and ratings for CYTR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CYTR
CUSIPN/A
Phone310-826-5648

Debt

Debt-to-Equity RatioN/A
Current Ratio1.92
Quick Ratio1.92

Price-To-Earnings

Trailing P/E Ratio-0.86
Forward P/E Ratio-1.34
P/E GrowthN/A

Sales & Book Value

Annual Sales$100,000.00
Price / Sales433.96
Cash FlowN/A
Price / CashN/A
Book Value$0.63 per share
Price / Book2.05

Profitability

EPS (Most Recent Fiscal Year)($1.52)
Net Income$-34,980,000.00
Net MarginsN/A
Return on Equity-137.27%
Return on Assets-55.06%

Miscellaneous

Employees20
Outstanding Shares33,640,000

CytRx (NASDAQ:CYTR) Frequently Asked Questions

What is CytRx's stock symbol?

CytRx trades on the NASDAQ under the ticker symbol "CYTR."

When did CytRx's stock split? How did CytRx's stock split work?

Shares of CytRx reverse split on the morning of Wednesday, November 1st 2017. The 1-6 reverse split was announced on Friday, October 27th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 31st 2017. An investor that had 100 shares of CytRx stock prior to the reverse split would have 17 shares after the split.

How were CytRx's earnings last quarter?

CytRx Co. (NASDAQ:CYTR) posted its earnings results on Friday, May, 11th. The biotechnology company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.09. View CytRx's Earnings History.

When is CytRx's next earnings date?

CytRx is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for CytRx.

What price target have analysts set for CYTR?

1 equities research analysts have issued 1-year price targets for CytRx's stock. Their predictions range from $5.00 to $5.00. On average, they expect CytRx's stock price to reach $5.00 in the next twelve months. View Analyst Ratings for CytRx.

Who are some of CytRx's key competitors?

Who are CytRx's key executives?

CytRx's management team includes the folowing people:
  • Mr. Steven A. Kriegsman, Chairman & CEO (Age 76)
  • Mr. John Y. Caloz, Chief Financial Officer (Age 66)
  • Mr. Eric L. Curtis, Pres & COO
  • Dr. Felix Kratz Ph.D., Sr. VP, Drug Devel. (Age 55)
  • Dr. André Warnecke Ph.D., Sr. Director of Drug Discovery

Has CytRx been receiving favorable news coverage?

Media coverage about CYTR stock has been trending somewhat positive on Friday, according to Accern Sentiment. The research group scores the sentiment of press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. CytRx earned a news sentiment score of 0.07 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 46.56 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Who are CytRx's major shareholders?

CytRx's stock is owned by many different of institutional and retail investors. Top institutional shareholders include SABBY MANAGEMENT, LLC (9.22%). View Institutional Ownership Trends for CytRx.

How do I buy shares of CytRx?

Shares of CYTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CytRx's stock price today?

One share of CYTR stock can currently be purchased for approximately $1.29.

How big of a company is CytRx?

CytRx has a market capitalization of $44.40 million and generates $100,000.00 in revenue each year. The biotechnology company earns $-34,980,000.00 in net income (profit) each year or ($1.52) on an earnings per share basis. CytRx employs 20 workers across the globe.

How can I contact CytRx?

CytRx's mailing address is 11726 SAN VICENTE BOULEVARD SUITE 650, LOS ANGELES CA, 90049. The biotechnology company can be reached via phone at 310-826-5648 or via email at [email protected]


MarketBeat Community Rating for CytRx (CYTR)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  262 (Vote Outperform)
Underperform Votes:  179 (Vote Underperform)
Total Votes:  441
MarketBeat's community ratings are surveys of what our community members think about CytRx and other stocks. Vote "Outperform" if you believe CYTR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYTR will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

CytRx (NASDAQ:CYTR) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for CytRx in the last 12 months. Their average twelve-month price target is $5.00, suggesting that the stock has a possible upside of 287.60%. The high price target for CYTR is $5.00 and the low price target for CYTR is $5.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $5.00$24.00$24.00$24.00
Price Target Upside: 287.60% upside396.46% upside396.46% upside396.46% upside

CytRx (NASDAQ:CYTR) Consensus Price Target History

Price Target History for CytRx (NASDAQ:CYTR)

CytRx (NASDAQ:CYTR) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/23/2018HC WainwrightBoost Price TargetBuy ➝ Buy$4.00 ➝ $5.00LowView Rating Details
3/21/2017AegisReiterated RatingBuyMediumView Rating Details
11/14/2016FBR & CoSet Price TargetBuy$18.00N/AView Rating Details
7/15/2016Jefferies GroupReiterated RatingHold$15.00 ➝ $4.50N/AView Rating Details
7/12/2016S&P Equity ResearchLower Price Target$6.24 ➝ $4.50N/AView Rating Details
(Data available from 5/25/2016 forward)

Earnings

CytRx (NASDAQ:CYTR) Earnings History and Estimates Chart

Earnings by Quarter for CytRx (NASDAQ:CYTR)

CytRx (NASDAQ:CYTR) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.96 EPS
Next Year EPS Consensus Estimate: $-0.8 EPS

CytRx (NASDAQ CYTR) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2018        
5/11/2018Q1 2018($0.24)($0.15)ViewN/AView Earnings Details
3/19/2018Q4 2017($0.16)$0.10 millionViewListenView Earnings Details
11/8/2017Q3 2017($0.33)ViewN/AView Earnings Details
8/3/2017Q2 2017($0.42)ViewN/AView Earnings Details
5/10/2017Q1 2017($0.60)ViewN/AView Earnings Details
3/15/2017Q4 2016($0.66)($0.60)$0.10 millionViewN/AView Earnings Details
11/9/2016Q3 2016($0.96)($0.78)ViewN/AView Earnings Details
7/29/2016Q2($1.14)($1.62)$0.10 millionViewN/AView Earnings Details
5/11/2016Q116($1.56)($1.14)ViewN/AView Earnings Details
3/11/2016Q4 2015($1.20)($2.10)$0.10 millionViewN/AView Earnings Details
11/3/2015Q315($1.44)($1.02)ViewN/AView Earnings Details
8/3/2015Q215($1.62)($1.50)ViewN/AView Earnings Details
5/1/2015Q115($1.26)($1.68)ViewN/AView Earnings Details
3/10/2015Q4 2014($1.62)($1.44)$0.10 millionViewN/AView Earnings Details
11/4/2014Q314($1.50)($0.60)ViewN/AView Earnings Details
8/6/2014Q214($1.20)($1.68)ViewN/AView Earnings Details
5/1/2014Q1 2014($1.08)ViewN/AView Earnings Details
3/5/2014($1.02)($1.50)$0.10 millionViewN/AView Earnings Details
10/29/2013Q313($1.32)($1.98)$0.20 millionViewN/AView Earnings Details
8/6/2013Q2 2013($1.14)($0.66)$0.20 millionViewN/AView Earnings Details
5/9/2013Q113($0.90)($1.38)ViewN/AView Earnings Details
3/11/2013Q4 2012($1.20)($1.26)ViewN/AView Earnings Details
11/9/2012Q312$0.42ViewN/AView Earnings Details
8/9/2012Q2 2012($1.86)($1.34)ViewN/AView Earnings Details
5/10/2012Q1 2012($1.68)($1.76)ViewN/AView Earnings Details
3/13/2012Q4 2011($1.68)($1.72)ViewN/AView Earnings Details
11/8/2011Q3 2011($1.68)($1.05)ViewN/AView Earnings Details
8/9/2011Q2 2011($2.10)($1.43)ViewN/AView Earnings Details
5/5/2011Q1 2011($1.26)($2.60)ViewN/AView Earnings Details
3/11/2011Q4 2010$2.27ViewN/AView Earnings Details
11/8/2010Q3 2010($2.10)($1.68)ViewN/AView Earnings Details
8/9/2010Q2 2010($2.10)($1.89)ViewN/AView Earnings Details
5/6/2010Q1 2010($1.68)($1.81)ViewN/AView Earnings Details
3/15/2010Q4 2009($1.68)($1.26)ViewN/AView Earnings Details
11/9/2009Q3 2009$0.42$1.51ViewN/AView Earnings Details
8/10/2009Q2 2009($1.68)($1.01)ViewN/AView Earnings Details
5/12/2009Q1 2009($1.68)($1.81)ViewN/AView Earnings Details
3/13/2009Q4 2008($1.68)($1.76)ViewN/AView Earnings Details
11/7/2008Q3 2008($1.68)($1.34)ViewN/AView Earnings Details
8/12/2008Q2 2008($2.52)($1.68)ViewN/AView Earnings Details
5/20/2008Q1 2008($3.36)($2.85)ViewN/AView Earnings Details
4/2/2008Q4 2007($2.94)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

CytRx (NASDAQ:CYTR) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

CytRx (NASDAQ CYTR) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.30%
Institutional Ownership Percentage: 5.60%
Insider Trading History for CytRx (NASDAQ:CYTR)
Institutional Ownership by Quarter for CytRx (NASDAQ:CYTR)

CytRx (NASDAQ CYTR) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/3/2013Scott Bradford Pattersonmajor shareholderBuy284,979$2.44$695,348.764,912,584View SEC Filing  
11/7/2013Scott Bradford PattersonMajor ShareholderBuy50,000$2.06$103,000.00View SEC Filing  
4/1/2013Scott Bradford PattersonMajor ShareholderBuy4,083$2.70$11,024.10View SEC Filing  
3/20/2013Scott Bradford PattersonMajor ShareholderBuy3,980$2.61$10,387.80View SEC Filing  
3/13/2013Scott Bradford PattersonMajor ShareholderBuy55,360$2.67$147,811.20View SEC Filing  
10/22/2012Scott Bradford PattersonMajor ShareholderBuy180,000$2.51$451,800.00View SEC Filing  
10/18/2012Scott Bradford PattersonMajor ShareholderBuy1,200,000$2.50$3,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

CytRx (NASDAQ CYTR) News Headlines

Source:
DateHeadline
CytRx (CYTR) PT Raised to $4.50CytRx (CYTR) PT Raised to $4.50
www.americanbankingnews.com - May 23 at 1:35 PM
CytRx Corporation Highlights NantCell Incs Aldoxorubicin Clinical Data to be Presented at the American Society of ...CytRx Corporation Highlights NantCell Inc's Aldoxorubicin Clinical Data to be Presented at the American Society of ...
www.prnewswire.com - May 17 at 10:02 AM
CytRx Corporation Highlights NantCell Incs Aldoxorubicin Clinical Data to be Presented at the American Society of Clinical Oncology 2018 Annual MeetingCytRx Corporation Highlights NantCell Inc's Aldoxorubicin Clinical Data to be Presented at the American Society of Clinical Oncology 2018 Annual Meeting
finance.yahoo.com - May 17 at 10:02 AM
BRIEF-CytRx Announces Closing Of $7.0 Mln Registered Direct OfferingBRIEF-CytRx Announces Closing Of $7.0 Mln Registered Direct Offering
www.reuters.com - May 16 at 10:35 AM
CytRx Announces Closing of $7.0 Million Registered Direct OfferingCytRx Announces Closing of $7.0 Million Registered Direct Offering
www.prnewswire.com - May 15 at 4:52 PM
Vericel (VCEL) vs. CytRx (CYTR) Financial SurveyVericel (VCEL) vs. CytRx (CYTR) Financial Survey
www.americanbankingnews.com - May 14 at 5:25 AM
BRIEF-Cytrx Announces $7.0 Million Registered Direct OfferingBRIEF-Cytrx Announces $7.0 Million Registered Direct Offering
www.reuters.com - May 11 at 11:07 AM
CytRx Announces $7.0 Million Registered Direct OfferingCytRx Announces $7.0 Million Registered Direct Offering
finance.yahoo.com - May 11 at 11:07 AM
CytRx announces $7M registered direct offering; shares down 28% premarketCytRx announces $7M registered direct offering; shares down 28% premarket
seekingalpha.com - May 11 at 9:52 AM
 Brokerages Anticipate CytRx (CYTR) Will Announce Earnings of -$0.25 Per Share Brokerages Anticipate CytRx (CYTR) Will Announce Earnings of -$0.25 Per Share
www.americanbankingnews.com - May 11 at 3:14 AM
CytRx (CYTR) Announces Quarterly  Earnings Results, Beats Expectations By $0.09 EPSCytRx (CYTR) Announces Quarterly Earnings Results, Beats Expectations By $0.09 EPS
www.americanbankingnews.com - May 9 at 10:28 PM
CytRx: 1Q Earnings SnapshotCytRx: 1Q Earnings Snapshot
finance.yahoo.com - May 8 at 9:50 AM
CytRx Reports First Quarter 2018 Financial ResultsCytRx Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 8 at 9:50 AM
CytRx Corporation to Present at OneMed NYC Oncology Investor Conference 2018CytRx Corporation to Present at OneMed NYC Oncology Investor Conference 2018
finance.yahoo.com - May 7 at 10:15 AM
CytRx (CYTR) Stock Rating Upgraded by ValuEngineCytRx (CYTR) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - May 3 at 7:57 PM
HC Wainwright Reiterates Buy Rating for CytRx (CYTR)HC Wainwright Reiterates Buy Rating for CytRx (CYTR)
www.americanbankingnews.com - May 3 at 4:31 PM
Benzingas Top Upgrades, Downgrades For May 3, 2018Benzinga's Top Upgrades, Downgrades For May 3, 2018
www.benzinga.com - May 3 at 4:05 PM
CytRx Corporation Names Eric L. Curtis as Its President and Chief Operating OfficerCytRx Corporation Names Eric L. Curtis as Its President and Chief Operating Officer
finance.yahoo.com - May 3 at 9:47 AM
CytRx (CYTR) Set to Announce Quarterly Earnings on TuesdayCytRx (CYTR) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - May 1 at 7:46 AM
CytRx Corporation Highlights NantCell Incs Aldoxorubicin Abstract Selected for Poster Presentation at the American ...CytRx Corporation Highlights NantCell Inc's Aldoxorubicin Abstract Selected for Poster Presentation at the American ...
www.prnewswire.com - April 30 at 10:47 AM
CytRx Corporation Highlights NantCell Incs Aldoxorubicin Abstract Selected for Poster Presentation at the American Society of Clinical Oncology 2018 Annual MeetingCytRx Corporation Highlights NantCell Inc's Aldoxorubicin Abstract Selected for Poster Presentation at the American Society of Clinical Oncology 2018 Annual Meeting
finance.yahoo.com - April 30 at 10:47 AM
CytRx (CYTR) Upgraded to Sell by ValuEngineCytRx (CYTR) Upgraded to Sell by ValuEngine
www.americanbankingnews.com - April 18 at 4:44 PM
BRIEF-Cytrx Presents Statistically Significant Breakthrough Data For Its Albumin Binding Ultra High Potency Ladr Drug ...BRIEF-Cytrx Presents Statistically Significant Breakthrough Data For Its Albumin Binding Ultra High Potency Ladr Drug ...
www.reuters.com - April 18 at 10:06 AM
CytRx Presents Statistically Significant Breakthrough Data for Its Albumin Binding Ultra High Potency LADR™ Drug ...CytRx Presents Statistically Significant Breakthrough Data for Its Albumin Binding Ultra High Potency LADR™ Drug ...
www.prnewswire.com - April 18 at 10:06 AM
CytRx Presents Statistically Significant Breakthrough Data for Its Albumin Binding Ultra High Potency LADR™ Drug Candidates at the American Association for Cancer Research 2018 Annual MeetingCytRx Presents Statistically Significant Breakthrough Data for Its Albumin Binding Ultra High Potency LADR™ Drug Candidates at the American Association for Cancer Research 2018 Annual Meeting
finance.yahoo.com - April 18 at 10:06 AM
CytRx (CYTR) Rating Lowered to Sell at ValuEngineCytRx (CYTR) Rating Lowered to Sell at ValuEngine
www.americanbankingnews.com - April 13 at 1:35 PM
CytRx Corporation to Present Breakthrough Data on Albumin Binding Ultra High Potency LADR™ Drug Candidates at ...CytRx Corporation to Present Breakthrough Data on Albumin Binding Ultra High Potency LADR™ Drug Candidates at ...
www.prnewswire.com - April 9 at 10:23 AM
CytRx Corporation to Present Breakthrough Data on Albumin Binding Ultra High Potency LADR™ Drug Candidates at the AACR 2018 ConferenceCytRx Corporation to Present Breakthrough Data on Albumin Binding Ultra High Potency LADR™ Drug Candidates at the AACR 2018 Conference
finance.yahoo.com - April 9 at 10:23 AM
CytRx (CYTR) Downgraded by ValuEngine to "Strong Sell"CytRx (CYTR) Downgraded by ValuEngine to "Strong Sell"
www.americanbankingnews.com - March 31 at 2:40 PM
Edited Transcript of CYTR earnings conference call or presentation 19-Mar-18 3:00pm GMTEdited Transcript of CYTR earnings conference call or presentation 19-Mar-18 3:00pm GMT
finance.yahoo.com - March 29 at 10:29 AM
CytRx (CYTR) Reports Q4 Loss of $1.46CytRx (CYTR) Reports Q4 Loss of $1.46
www.streetinsider.com - March 19 at 10:37 AM
CytRx Corporation to Host Earnings CallCytRx Corporation to Host Earnings Call
finance.yahoo.com - March 19 at 10:37 AM
CytRx reports 4Q lossCytRx reports 4Q loss
finance.yahoo.com - March 19 at 10:37 AM
CytRx Reports 2017 Financial ResultsCytRx Reports 2017 Financial Results
finance.yahoo.com - March 19 at 10:37 AM
CytRx (CYTR) Issues Quarterly  Earnings ResultsCytRx (CYTR) Issues Quarterly Earnings Results
www.americanbankingnews.com - March 19 at 7:20 AM
CytRx to Present at the 28th Annual Oppenheimer Healthcare Conference - PR Newswire (press release)CytRx to Present at the 28th Annual Oppenheimer Healthcare Conference - PR Newswire (press release)
www.prnewswire.com - March 16 at 4:13 PM
CytRx to Present at the 28th Annual Oppenheimer Healthcare ConferenceCytRx to Present at the 28th Annual Oppenheimer Healthcare Conference
finance.yahoo.com - March 16 at 10:58 AM
BRIEF-CytRx Selects Four New LADR™ Ultra High Potency Drug Candidates For Advancement Toward Clinical TrialsBRIEF-CytRx Selects Four New LADR™ Ultra High Potency Drug Candidates For Advancement Toward Clinical Trials
www.reuters.com - March 15 at 10:51 AM
CytRx Selects Four New LADR™ Ultra High Potency Drug Candidates for Advancement Toward Clinical TrialsCytRx Selects Four New LADR™ Ultra High Potency Drug Candidates for Advancement Toward Clinical Trials
finance.yahoo.com - March 15 at 10:51 AM
CytRx to Hold Year End 2017 Financial Results Conference Call and Webcast on Monday, March 19, 2018CytRx to Hold Year End 2017 Financial Results Conference Call and Webcast on Monday, March 19, 2018
finance.yahoo.com - March 12 at 4:02 PM
CytRx (CYTR) to Release Quarterly Earnings on TuesdayCytRx (CYTR) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - March 6 at 2:32 AM
CytRx to Present at the 30th Annual ROTH ConferenceCytRx to Present at the 30th Annual ROTH Conference
finance.yahoo.com - March 5 at 10:59 AM
Are Earnings Prospects Improving For Loss-Making CytRx Corporation’s (NASDAQ:CYTR)?Are Earnings Prospects Improving For Loss-Making CytRx Corporation’s (NASDAQ:CYTR)?
finance.yahoo.com - March 3 at 10:36 AM
CytRx Announces Key Addition to Corporate Development TeamCytRx Announces Key Addition to Corporate Development Team
finance.yahoo.com - March 1 at 10:03 AM
CytRx hires advisor to assist in identifying partnering opportunities for LADR conjugatesCytRx hires advisor to assist in identifying partnering opportunities for LADR conjugates
seekingalpha.com - February 28 at 4:11 PM
BRIEF-Cytrx Corp Announces Its Entry Into A Definitive Agreement With Destum PartnersBRIEF-Cytrx Corp Announces Its Entry Into A Definitive Agreement With Destum Partners
www.reuters.com - February 28 at 10:30 AM
CytRx Announces Expansion of Pharma Partnering Activities for Its LADR™ Ultra-High Potency Drug CandidatesCytRx Announces Expansion of Pharma Partnering Activities for Its LADR™ Ultra-High Potency Drug Candidates
finance.yahoo.com - February 28 at 10:30 AM
CytRx Announces the Presentation of New LADR™ Candidate Data at the American Association for Cancer Research 2018 Annual MeetingCytRx Announces the Presentation of New LADR™ Candidate Data at the American Association for Cancer Research 2018 Annual Meeting
finance.yahoo.com - February 22 at 9:57 AM
CytRx Corporation to Present at the 2018 BIO CEO & Investor ConferenceCytRx Corporation to Present at the 2018 BIO CEO & Investor Conference
finance.yahoo.com - February 6 at 3:20 PM
CytRx Corporation Highlights Second NantCell Inc. Clinical Trial Evaluating Immuno-Oncology Agents and Cell-based Therapies in Combination with Aldoxorubicin in Patients with Advanced Squamous Cell CarcinomaCytRx Corporation Highlights Second NantCell Inc. Clinical Trial Evaluating Immuno-Oncology Agents and Cell-based Therapies in Combination with Aldoxorubicin in Patients with Advanced Squamous Cell Carcinoma
finance.yahoo.com - February 5 at 3:20 PM

SEC Filings

CytRx (NASDAQ:CYTR) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

CytRx (NASDAQ:CYTR) Income Statement, Balance Sheet and Cash Flow Statement

Chart

CytRx (NASDAQ CYTR) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.